In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

Division of Johnson & Johnson
www.janssenpharmaceuticalsinc.com

Latest From Janssen Pharmaceuticals Inc.

Behind-The-Scenes Battles As Opioid MDL Jury Trial Nears

Expert witness "battle plan," requests for summary judgment, and squabble over DEA drug distribution data offer preview of the first US bellwether trial against opioid manufacturers, distributors and pharmacies.

 
Legal Issues Advertising, Marketing & Sales

Opioid Litigation Pushes American Pain Society Into Bankruptcy

Labeled by plaintiffs as a 'front group' for opioid makers, the organization was pulled into the multidistrict litigation in Ohio and filed for Chapter 7 bankruptcy in June. It ceased operations in July.

Legal Issues Policy

Will Slew of Patent Bills Lower Drug Prices?

Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.

Legislation Pricing Debate

MSN Labs Gets FDA Nod For Zytiga Rival

India’s MSN Laboratories has won approval from the US health regulator to market its prostate cancer drug abiraterone acetate, a generic version of Janssen’s Zytiga. The clearance marks the latest in a string of FDA approvals for the fast-growing generic drugs company.

Strategy Generic Drugs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register